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Abstract
Topical hemostats, fibrin sealants, and surgical adhesives are regularly used in a variety of surgical
procedures involving multiple disciplines. Generally, these adjuncts to surgical hemostasis are
valuable means for improving wound visualization, reducing blood loss or adding tissue adherence;
however, some of these agents are responsible for under-recognized adverse reactions and
outcomes. Bovine thrombin, for example, is a topical hemostat with a long history of clinical
application that is widely used alone or in combination with other hemostatic agents.
Hematologists and coagulation experts are aware that these agents can lead to development of an
immune-mediated coagulopathy (IMC). A paucity of data on the incidence of IMC contributes to
under-recognition and leaves many surgeons unaware that this clinical entity, originating from
normal immune responses to foreign antigen exposure, requires enhanced post-operative vigilance
and judicious clinical judgment to achieve best outcomes.
Postoperative bleeding may result from issues such as loosened ties or clips or the occurrence of
a coagulopathy due to hemodilution, vitamin K deficiency, disseminated intravascular coagulation
(DIC) or post-transfusion, post-shock coagulopathic states. Other causes, such as liver disease, may
be ruled out by a careful patient history and common pre-operative liver function tests. Less
common are coagulopathies secondary to pathologic immune responses. Such coagulopathies
include those that may result from inherent patient problems such as patients with an immune
dysfunction related to systemic lupus erythrematosus (SLE) or lymphoma that can invoke
antibodies against native coagulation factors. Medical interventions may also provoke antibody
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formation in the form of self-directed anti-coagulation factor antibodies, that result in problematic
bleeding; it is these iatrogenic post-operative coagulopathies, including those associated with
bovine thrombin exposure and its clinical context, that this panel was convened to address.
The RETACC panel's goal was to attain a logical consensus by reviewing the scientific evidence
surrounding IMC and to make recommendations for the clinical recognition, diagnosis and
evaluation, and clinical management of these complications. In light of the under-recognition and
under-reporting of IMC, and given the associated morbidity, utilization of health care resources,
and potential economic impact to hospitals, the panel engaged in a detailed review of peer-
reviewed reports of bovine thrombin associated IMC. From that clinical knowledge base,
recommendations were developed to guide clinicians in the recognition, diagnosis, and
management of this challenging condition.
Findings
Recognizing Immune-Mediated Coagulopathy Associated 
with Bovine Thrombin
IMC is thought to be a relatively uncommon, under-rec-
ognized, and iatrogenic medical condition that can result
from exposure to non-human coagulation proteins, such
as porcine FVIII and bovine thrombin [1,2]. Beginning in
1989, coincident with the rising utilization of bovine
thrombin preparations for topical surgical hemostasis, a
number of case reports of post-surgical bovine thrombin
associated IMC began to appear in the literature [3-35].
IMC occurring unexpectedly in post-surgical patients who
were either exposed or re-exposed to bovine thrombin
preparations have continued to be reported in nearly all
surgical specialties, though cardiac, pediatric and ortho-
pedic/neurosurgical case reports comprise the majority
(Table 1). Interestingly, in the panel's literature review of
64 cases with known or presumed surgical exposure to
topical bovine thrombin, there is a near equal representa-
tion of bleeding versus non-bleeding case presentations.
Given that the majority of data on this condition is from
case reports, the true incidence is unknown, but numer-
ous reports have appeared in the literature since the year
2000 [3,6,7,11,17-19,22,24,25,27-29,31,36]. The true
incidence of IMC associated with bovine thrombin
remains unknown due to the lack of a clinical trial
designed to answer that question. The result is a mixture
of low awareness and confusion in the clinical commu-
nity about the delayed onset of antibody formation and
the challenges posed by masking due to coexistent coagu-
lopathies (e.g., consumptive, dilutive, drug-induced, etc.).
This panel's extensive review found that IMC always has a
delayed onset following surgical procedures where bovine
thrombin was used; none of the 61 cases reviewed (where
time from exposure to clinical presentation was
recorded), presented with symptoms or laboratory abnor-
malities earlier than 5 days following exposure (Table 2).
The mean time to clinical presentation or laboratory
abnormality (whichever was earlier) was 32 days, high-
lighting the potential for significant delay in onset and the
potential for out of hospital risk. The most common time
to presentation reported was 8 days (mode), while the
median time to presentation was 11 days. Earlier clinical
presentation in the 7 to 14 day time frame has most often
been attributed to secondary exposure, where a second
surgical exposure to a bovine thrombin preparation acts
as a type of immunologic booster for antibody develop-
ment [37,38]. Typically, primary exposure involves a
more delayed clinical presentation due to the need for de
novo maturation of the plasma B-cell antibody response.
This obligatory time frame, dictated by the cellular and
humoral mechanisms necessary for antibody formation,
can delay diagnosis or even conceal the occurrence of
these events from the surgeons employing these agents.
The panel subscribe that with a proper index of suspicion,
Table 1: Reports of bleeding and non-bleeding IMC
Bleeding Cases Non-Bleeding Cases Total†
Cardiac 21 19 40
Ortho/Neurosurgery 5 5 10
Others 6 8 14
† Pediatric cardiac cases accounted for 9 of the reported cardiac cases
Number of patients who presented with bleeding or laboratory abnormality among 64 cases that contained reports of a surgical setting where 
known or presumed bovine thrombin exposure occurred [3-35].
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the resulting delays in recognition and treatment are pre-
ventable as are the increased morbidity, mortality,
increased length of hospitalization and increased utiliza-
tion of blood products that accompany this acquired dis-
order.
The evidence indicates that bovine thrombin related IMC
results from antibodies that develop in response to bovine
thrombin exposure and its associated proteins such as
bovine factor V [18,31,39-41]. Bovine thrombin prepara-
tions have been reported to have in addition to bovine
thrombin, bovine factors V, IX, and X as well as non-spe-
cific, immunoreactive proteins presumed to be protein
fragments [42]. These antibodies may cross-react with
human coagulation proteins, significantly interfering with
the normal clotting cascade. Clinical sequelae range from
individuals with abnormal prothrombin time (PT), acti-
vated partial thromboplastin time (aPTT) and thrombin
time (TT) who are asymptomatic and at risk for bleeding
[18,25,28,29,31] to anaphylaxis [36], hemorrhage
[19,27], or other critical adverse events [17,19,27,43,44].
Despite prolonged efforts to improve manufacturing
methods and remove contaminating proteins
[18,38,40,41,45], there is no clinical evidence that bovine
thrombin antigenicity has been reduced.
Most severe bleeding episodes occur following repeated
exposure to bovine thrombin [34,46] and although his-
tory and documented use are often the best indication of
previous bovine thrombin exposure, charts or pharmacy
records can be incomplete. Accordingly, due to the wide-
spread use of bovine thrombin in many different types of
surgery, prior exposure can be difficult to determine in
some patients. Even if documentation of prior exposure is
available, it is impossible to predict whether antibodies
will form or clinical sequelae will result. However, when
presented with a patient with difficult to explain coagu-
lopathy, a history that includes previous bovine thrombin
exposure or procedures where it was likely used should
raise suspicion of the potential for IMC as an etiology.
Evaluation and diagnosis
IMC should be included in differential diagnosis when
there is unexplained postoperative bleeding and/or
hematoma, unexplained PT, aPTT or TT in the absence of
bleeding, an exaggerated response to anticoagulants in the
post-operative period, or bleeding unresponsive to con-
ventional treatment. Whether caused by antibodies to fac-
tor V or thrombin, IMC following secondary exposure to
bovine thrombin generally begins between 7 – 14 days
after repeated exposure to bovine thrombin; in the cases
reviewed by the panel no patient presented with labora-
tory or symptomatic IMC earlier than 5 days following
exposure (Table 2). Thus, patients may be at risk for
delayed post-operative bleeding, especially those who are
hospitalized more than a week after surgery; complex
post-surgical recovery is presumed to be a risk factor for a
more severe bleeding presentation. In this review, the
presence of cross-reacting antibodies to factor V
accounted for over 85% (28/32) in both the bleeding
cases as well as the cases presenting with laboratory
abnormalities alone (Table 3). Patients presenting with
laboratory abnormalities in the late post-operative period
are at risk for spontaneous hemorrhage. Relatively asymp-
tomatic coagulopathy in discharged patients may go
unrecognized exposing them to the inherent hemorrhagic
risks of an unrecognized bleeding disorder. Auto-directed
antibodies can be persistent, extending over a period of
months or years [6,8,31,43]. However, clinical presenta-
tion of IMC may occur 1 month or more after an initial
bovine thrombin exposure [17,43]. With subsequent
exposures, the appearance of antibodies, prolonged coag-
ulation tests, and clinical complications can occur earlier,
though no cases have been reported earlier than 5 days
following re-exposure [46]. Therefore, bovine thrombin-
Table 2: Time from bovine thrombin exposure to clinical 
presentation of IMC
Total
(n = 61)
Mean (days) 32
Median (days) 11
Mode (days) 8
Standard Dev (days) 65.8
95% CI (days) 25–49
Range (days) 5–365
Summary statistics from review of 61 cases where time from known 
or presumed exposure were documented [3-10,12-18,20-28,30-35].
Table 3: Number of patients presenting with either anti- Factor 
IIa (thrombin) inhibitor, anti-Factor V (FV) inhibitor, or both
Bleeding Cases
N = 32
Non-Bleeding Cases
N = 32
Total
N = 64
Inhibitor Type n (%) n (%) n (%)
FIIa 4 (13) 4 (12) 8 (12)
FV 17 (53) 15 (47) 32 (50)
FIIa and FV 11 (34) 13 (41) 24 (38)
Sorted by clinical presentation and contained reports of a surgical 
setting where known or presumed bovine thrombin exposure 
occurred [3-35].
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associated IMC should be suspected when there is unex-
pected post-operative bleeding that is not explained by
common causes of post-operative coagulopathy. It should
also be suspected for post-surgical patients who have
abnormal coagulation tests upon return for postoperative
follow-up, management of a surgical complication or
prior to another surgical procedure.
The first step in evaluation and diagnosis of IMC is to
measure PT and aPTT (Figure 1) [47]. If these tests are
abnormal, common causes for post-surgical coagulopathy
should be ruled out. These include surgical bleeding with
hemodilution, DIC, vitamin K deficiency, and thrombo-
cytopenia. In IMC, PT and aPTT will be persistently ele-
vated as other common causes of post-surgical
coagulopathy are eliminated. It should be noted that TT
using human thrombin reagents may not be a reliable
screening test and should not be used as a definitive deter-
mination of IMC. If IMC remains in the differential diag-
nosis after excluding other potential causes of acquired
coagulopathy, consultation with a hematologist who is an
expert in coagulation testing would be prudent.
Diagnosis of immune-mediated coagulopathy (IMC)Figure 1
Diagnosis of immune-mediated coagulopathy (IMC). In response to elevated PT/aPTT, IMC should be considered in 
the differential diagnosis for post-operative coagulopathy. Assays to rule out common causes of coagulopathies and mixing 
studies should be conducted. If the mixing study fails to correct, an inhibitor should be suspected. A hematology consult should 
be requested and factor assays conducted to confirm the diagnosis. (PT = prothrombin time; PTT = activated partial thrombo-
plastin time; FFP = fresh frozen plasma).
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In the presence of elevated PT and aPTT, a plasma mixing
study should be ordered along with other laboratory stud-
ies (i.e., D-dimer, fibrinogen). Ideally, these studies
should be ordered as soon as prolonged PT and aPTT are
observed and before intervention of any kind, including
administration of blood products. The clotting time of a
1:1 mix of patient plasma with normal pooled plasma
should be evaluated immediately and at 60 and 120 min-
utes after incubation at 37°C. If the mixing study fails to
correct and the clotting time falls outside of the reference
range, then an inhibitor such as an antibody to a coagula-
tion factor should be suspected. It should be noted that a
mixing study is relatively insensitive for the early detec-
tion of a factor V inhibitor due to potentially low antibody
titer levels in the period immediately following antigen
exposure. However, if the PT and aPTT continue to be pro-
longed in the absence of a negative mixing test, the PT and
aPTT should be monitored daily in conjunction with
repeated mixing studies in any actively bleeding patient.
If not already initiated, a hematology and/or blood bank
consult as well as confirmatory testing should follow a
positive result from the mixing study. Laboratory evalua-
tion should include specific quantitative assays of factor V
and factor V inhibitor, if available. Most laboratories can
evaluate factor V levels, but specific factor V antibody
assays are not readily available and must be specially per-
formed. More than one factor may be inhibited, but the
majority of bovine thrombin-associated IMC cases
reported in the literature have been linked to the develop-
ment of pathogenic factor V inhibitors [17,19,27,31,43].
Transfusion will confound more specific factor and inhib-
itor assays; therefore, before initiating therapy additional
blood samples should be obtained for more specific,
definitive testing. Necessary supportive care and treatment
should not be delayed while awaiting results since factor
assay results may not be available for several days.
Management of patients with an IMC
Management of patients with IMC may be challenging.
While the following recommendations reflect the consen-
sus reached by the panel, it is important to note that there
is limited large-scale clinical evidence supporting these
recommendations.
Patients can be divided into asymptomatic patients at risk
for bleeding and actively bleeding patients. For the 25
cases involving non-bleeding (at risk) patients reviewed
here, the most common interventions were prolonged
hospitalization for observation, trials of FFP and vitamin
K and in some cases immune-modulation with corticos-
teroids and/or intravenous immune globulin (IVIG)
(Table 4). The panel supports some of these reported prac-
tices such that for the non-bleeding patient, vitamin K in
conjunction with close observation is recommended.
These patients should also avoid elective surgery until lab-
oratory values normalize. The management of asympto-
matic patients is largely patient-specific since the risk of
spontaneous bleeding will vary as it does for patients on
therapeutic anticoagulant regimens. Therefore, it is advis-
able that clinicians use their best judgment as to when to
intervene. For patients with a history of comorbidities that
increase their risk for bleeding, immunosuppression (e.g.
corticosteroid therapy) may be reasonable. Prophylactic
therapy to prevent spontaneous bleeding has been used to
treat conditions like acquired hemophilia [48]. However,
if surgery is planned, prophylaxis with the platelet trans-
fusions necessary to treat the effects of anti-factor V anti-
bodies entails risk and there is no definitive data
demonstrating efficacy of this approach in otherwise
asymptomatic IMC patients. Patient counseling, surveil-
lance for complications, as well as serial factor assays and
PT/aPTT assays, should be continued for six to eight weeks
post-discharge or until values normalize. While the anti-
bodies may be long-lasting in some patients [46], case
reports suggest that the majority of the measurable inhib-
itors will eventually resolve. Parenthetically, skin testing
for bovine thrombin induced hypersensitivity is not a use-
ful screening technique because IMC is an IgG-mediated
phenomenon while skin testing typically measures IgE-
mediated mast cell degranulation and delayed T-cell
mediated immune activation. Importantly, the duration
of risk for an anamnestic response upon re-exposure is
Table 4: Reports of resource utilization in non-bleeding patients 
with IMC
Category Count %
Extended LOS 23 92.0%
Vit K 9 36.0%
FFP 8 32.0%
IVIG 5 20.0%
Plasmapheresis 5 20.0%
Steroids 4 16.0%
PLT 1 4.0%
Chemotherapy 0 0.0%
RBC 0 0.0%
LOS – Length of stay; FFP – fresh frozen plasma; Vit K – vitamin K; 
IVIG – intravenous immune globulin; PLT – platelets; RBC – red blood 
cells
Interventions among the 25 non-bleeding patients for whom case 
reports contained documentation of managing immune-mediated 
coagulopathy [3-5,8,9,11,12,14,15,18,21,22,24-26,28-31,35].
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unknown, suggesting that re-exposure should be avoided
and the patient counseled regarding bovine thrombin
immunogenicity.
Similarly, the management of actively bleeding IMC
patients is highly speculative and patient specific. In the
18 reviewed cases involving patients bleeding at the time
of clinical presentation, the most common reported inter-
ventions were prolonged hospitalization for supportive
care, blood product transfusion, and vitamin K (Table 5).
In 44% (8/18) of the cases, one or more interventions
aimed at immune modulation occurred. These interven-
tions included high dose corticosteroids, IVIG, plas-
mapheresis and potent chemotherapeutic immune
suppression (cyclophosphamide, vincristine, others).
Clearly, supportive care and replacement therapy with
blood products are recommended. Fresh frozen plasma
(FFP) and platelets should be administered in an effort to
supplement coagulation factors in the face of a coagulop-
athy and to overcome the inhibitor [49]. Platelets may be
particularly useful since normal platelets have factor V in
alpha granules that is protected from circulating inhibi-
tors (anti-factor antibodies). The immune system has a
large capacity for antibody production. In situations
where bleeding persists, further interventions designed to
reduce circulating antibody titer may be indicated. Plasma
exchange will accelerate inhibitor clearance and factor V
replacement [27]. However, plasmapheresis only removes
circulating antibody present in the intravascular space.
Thus, due to rapid reappearance of antibody in plasma
following redistribution from the larger extravascular
space, the benefits of plasmapheresis may be only tran-
sient and multiple procedures will likely be required due
to continued antibody production. In order to maintain
factor V levels, plasma is indicated as the replacement
fluid for plasmapheresis. In addition, there are inherent
risks associated with plasma exchange and vascular access
may be difficult to achieve in bleeding patients. Immuno-
suppressive therapy such as steroids, cyclophosphamide,
rituximab, or IVIG (except during plasmapheresis), may
be beneficial [17,19,28,29,31,50]. However, immunosup-
pression may take weeks to work. Therefore, immunosup-
pression alone is not sufficient for patients who are
actively bleeding and may work best in conjunction with
FFP and platelets. Because recombinant FVIIa (rFVIIa)
depends upon an intact common coagulation pathway,
rFVIIa is not recommended for treatment of actively
bleeding IMC patients [17,43]. These recommendations
are based upon a review of many case reports and not clin-
ical trials, which would be difficult in view of the inherent
difficulty in designing a trial where estimates of incidence
rate vary widely.
Once the patient has stopped bleeding, supportive care
and follow-up should continue until antibodies resolve
and PT/aPTT normalize. Further intervention may not be
required once hemostasis is achieved and if no other sur-
gical procedures are required. If the PT/aPTT is not resolv-
ing, a new mixing study and factor assays should be
ordered. If the PT does not begin to normalize and the fac-
tor V level is not recovering and a risk of spontaneous
hemorrhage remains, then immunosuppression with
IVIG or steroids may be indicated. The risks of immuno-
suppression in the post-surgical patient should be care-
fully weighed. As with non-bleeding patients with IMC,
post-hemorrhagic patients should be monitored until res-
olution of the inhibitor. In both asymptomatic and bleed-
ing patients where bovine thrombin-associated IMC has
been confirmed, patients should be counseled to avoid re-
exposure to bovine thrombin due to the risk for an anam-
nestic (B-memory cell mediated) response. If further inva-
sive procedures are planned, alternative topical hemostats
should be considered.
Conclusion
IMC is an iatrogenic and preventable medical condition
that continues to cause patient morbidity and mortality.
The panel's goal was to develop the recommendations
included in this brief communication as a means of help-
ing clinicians recognize, diagnose, and manage patients
with IMC. The diagnosis of IMC requires clinical aware-
ness and early re-evaluation of patient history; serial PT/
aPTT tests, mixing studies, and factor assays are essential
Table 5: Reports of resource utilization in bleeding patients with 
IMC
Category Count %
Extended LOS 18 100.0%
FFP 12 66.7%
RBC 10 55.6%
Vit K 10 55.6%
Steroids 8 44.4%
PLT 8 44.4%
IVIG 7 38.9%
Plasmapheresis 5 27.8%
Chemotherapy 3 16.7%
LOS – Length of stay; FFP – fresh frozen plasma; Vit K – vitamin K; 
IVIG – intravenous immune globulin; PLT – platelets; RBC – red blood 
cells
Interventions among the 18 bleeding patients for whom case reports 
contained documentation of managing immune-mediated 
coagulopathy [6,7,9,10,15-17,20,23,26,27,30,31,33,34].
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for the definitive diagnosis of this condition. While sup-
portive care is largely patient specific, a number of man-
agement options are available including replacement
transfusion, platelets, plasmapheresis, and immunosup-
pression. IMC is an avoidable condition and alternatives
to bovine thrombin should be considered in patients with
a history of unexplained post-operative bleeding. Avoid-
ing the use of bovine thrombin preparations altogether
would likely reduce the risk of bovine thrombin-associ-
ated IMC, thus avoiding the morbidity and extensive hos-
pital resource utilization that are associated with this
difficult to diagnose and manage condition.
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